PT-141

PT-141 research peptide primarily functions as a melanocortin receptor agonist, with high affinity for MC4R and MC1R, and notable activity at MC3R, triggering central nervous system signaling in hypothalamic regions such as the medial preoptic area to facilitate dopamine release and promote sexual desire and arousal pathways. Furthermore, unlike peripheral vasodilators, it exerts its effects through neurobiological modulation rather than direct vascular action, influencing presynaptic MC4R activation to increase neurotransmitter release while avoiding significant impacts on blood pressure or cardiovascular parameters in many models. Additionally, laboratory studies reveal enhanced erectile responses in psychogenic models and improved subjective desire in arousal investigations, with sustained effects observed post-administration. These central actions contribute to observed improvements in models of hypoactive sexual desire and erectile dysfunction, with recent research emphasizing its reassuring potential for balanced, brain-mediated modulation of sexual motivation and function free from typical PDE-5 inhibitor limitations.

• Melanocortin receptor studies
• CNS pathway analysis
• Novel agonist mechanism research
• Receptor selectivity evaluation

• Diamond LE et al. J Sex Med. 2004;1(Suppl 1):60-65
• Rosen RC et al. J Sex Med. 2017;14(9):1142-1150
• Clayton AH et al. JAMA. 2019;321(21):2123-2133
• King SH et al. Curr Opin Investig Drugs. 2007;8(9):746-752
• Molinoff PB et al. Ann N Y Acad Sci. 2003;994:96-102